MedTrace Logo

CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

NCT03113188 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2021-03-10

No results posted yet for this study

Summary

This is a multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination administered once every 21 days to patients with advanced solid tumors.

Conditions

Interventions

DRUG

CBP501

CBP501, CDDP plus Nivolumab

Sponsors & Collaborators

  • CanBas Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Geoffrey I Shapiro, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-25
Primary Completion
2021-02-15
Completion
2021-02-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03113188 on ClinicalTrials.gov